Docetaxel is approved for advanced prostate Ca

Docetaxel (Taxotere) has been approved by the FDA for the treatment of hormone-refractory metastatic prostate cancer when used in combination with prednisone.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria